TORONTO– Biomind Labs Inc. (NEO: BMND) (FSE: 3XI), a leading biotech company in fast-acting psychedelics, announces today the Company’s completion of the development of a novel thermosensitive nasal gel delivery system for its N, N-dimethyltryptamine (“DMT”) and 5-MeO-DMT product candidates. The product candidates are aimed at treating depression, anxiety, addictive disorders, eating disorders, and improving the quality of life of patients suffering from neurodegenerative disorders.
“We are pleased to announce that our scientific team has accomplished a major step in our molecule-to-market lifecycle by completing the development of a tailored drug delivery system for our DMT and 5-MeO-DMT product candidates. The delivery system has the potential to allow for a fast onset through easy administration as well as a potential decrease in side effects. It also has the potential to allow for decreased doses compared to the doses necessary to achieve similar results through other forms of systemic administration. Due to the seriousness of our targeted indications, we are committed to providing patients and the psychiatric community with novel pharmaceuticals that provide a comfortable, safe and efficient use”, commented Alejandro Antalich, CEO of Biomind Labs.
The Company’s design of the nasal gel consists of an adequate viscosity liquid, which turns into a mucoadhesive gel almost immediately after insertion into the nasal cavity upon contact with the mucosa at body temperature.
